Access count of this item: 0

Files in This Item:
This article will be available after a certain embargo period.
Please see the "Rights" information in item metadata display about embargo date.
Title: ニボルマブ治療により遅発性に間質性腎炎を発症した転移性腎細胞癌の1例
Other Titles: A Case of Late Onset Nivolumab-Induced Interstitial Nephritis in a Patient with Metastatic Renal Cell Carcinoma
Authors: 八田原, 広大  KAKEN_name
山﨑, 俊成  KAKEN_name
澤田, 篤郎  KAKEN_name
谷垣, 克哉  KAKEN_name
遠藤, 修一郎  KAKEN_name
寺本, 祐記  KAKEN_name
坂野, 遼  KAKEN_name
渕上, 靖史  KAKEN_name
鈴木, 良輔  KAKEN_name
藤原, 真希  KAKEN_name
飛田, 卓哉  KAKEN_name
吉野, 喬之  KAKEN_name
北, 悠希  KAKEN_name
後藤, 崇之  KAKEN_name
赤松, 秀輔  KAKEN_name
齊藤, 亮一  KAKEN_name
小林, 恭  KAKEN_name
井上, 貴博  KAKEN_name
小川, 修  KAKEN_name
Author's alias: Hattahara, Kodai
Yamasaki, Toshinari
Sawada, Atsuro
Tanigaki, Katsuya
Endo, Syuichiro
Teramoto, Yuki
Banno, Haruka
Fuchigami, Yasushi
Suzuki, Ryosuke
Fujiwara, Maki
Hida, Takuya
Yoshino, Takayuki
Kita, Yuki
Goto, Takayuki
Akamatsu, Shusuke
Saito, Ryoichi
Kobayashi, Takashi
Inoue, Takahiro
Ogawa, Osamu
Keywords: Nivolumab
Interstitial nephritis
Issue Date: 31-May-2019
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要 = Acta urologica Japonica
Volume: 65
Issue: 5
Start page: 157
End page: 161
Abstract: A 43-year-old man underwent nephrectomy for right renal cell carcinoma (cT3aN0M1 (PUL), clear cell carcinoma). Thereafter, he was treated with sunitinib for lung metastases as the first-line therapy for three months. Because lung metastases progressed and new bone metastases appeared, nivolumab was started for the second-line treatment. Although the cancer progression was suppressed by multidisciplinary treatment combined with systemic immunotherapy and local radiation therapy, he developed severe acute kidney injury with cortical swelling after eighteen months of nivolumab treatment. A diagnosis of acute interstitial nephritis induced by nivolumab was made based on biopsy findings. Treatment with prednisolone (1.0 mg/kg daily) led to a rapid improvement in renal function. We must consider the possibility of immunerelated adverse events, especially nivolumab-induced acute kidney injury, even after long-term treatment.
Rights: 許諾条件により本文は2020/06/01に公開
DOI: 10.14989/ActaUrolJap_65_5_157
URI: http://hdl.handle.net/2433/242270
PubMed ID: 31247693
Appears in Collections:Vol.65 No.5

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.